Press release
Investigation announced for Long-Term Investors in shares of IMARA Inc. (NASDAQ: IMRA)
An investigation on behalf of investors in IMARA Inc. (NASDAQ: IMRA) shares over potential wrongdoing at IMARA Inc. was announced.
Investors who purchased shares of IMARA Inc. (NASDAQ: IMRA) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain IMARA Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Boston, MA based IMARA Inc., a clinical-stage biopharmaceutical company, develops and commercializes therapeutics for patients with rare genetic disorders of hemoglobin. On or around March 11, 2020, IMARA Inc. (NASDAQ: IMRA) conducted its initial public offering ("IPO"), selling 4,700,000 shares of common stock priced at $16.00 per share.
On March 5, 2021, IMARA Inc. reported its financial results for the year ended December 31, 2020, which included a net loss of $49.2 million, compared to a net loss of $23.5 million for the prior year.
Shares of IMARA Inc. (NASDAQ: IMRA) declined to as low as $8.49 per share on March 5, 2021.
Those who purchased shares of IMARA Inc. (NASDAQ: IMRA) have certain options and should contact the Shareholders Foundation.
Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Investigation announced for Long-Term Investors in shares of IMARA Inc. (NASDAQ: IMRA) here
News-ID: 2279866 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for IMARA
Focal Segmental Glomerulosclerosis Market: Epidemiology, Therapies, Companies, D …
Focal Segmental Glomerulosclerosis therapies, such as LEQVIO (Inclisiran), Olpasiran (AMG 890), and others, are expected to boost the Focal Segmental Glomerulosclerosis Market in the upcoming years.
DelveInsight has launched a new report on "Focal Segmental Glomerulosclerosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology as well as the Focal Segmental Glomerulosclerosis market trends in the United States, EU5…
Beta thalassemia Market: Epidemiology, Therapies, Companies, DelveInsight | Nova …
Beta thalassemia emerging therapies, such as Mitapivat (AG-348), and others, are expected to boost the Beta thalassemia Market in the upcoming years.
DelveInsight has launched a new report on "Beta thalassemia - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Beta thalassemia, historical and forecasted epidemiology as well as the Beta thalassemia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom)…
Focal Segmental Glomerulosclerosis Treatment Market Size Report 2034 | Travere T …
DelveInsight's "Focal Segmental Glomerulosclerosis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of the Focal Segmental Glomerulosclerosis, historical and forecasted epidemiology and the FSGS market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Focal Segmental Glomerulosclerosis Market with DelveInsight's In-Depth Report @ Focal Segmental Glomerulosclerosis Market Size- https://www.delveinsight.com/sample-request/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways…
Focal Segmental Glomerulosclerosis Market Expected to rise, 2034 | Travere Thera …
The Focal Segmental Glomerulosclerosis market growth is driven by factors like increase in the prevalence of Focal Segmental Glomerulosclerosis, investments in research and development, entry of emerging therapies during the study period 2020-2034.
The Focal Segmental Glomerulosclerosis market report [https://www.delveinsight.com/report-store/focal-segmental-glomerulosclerosis-fsgs-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr] also offers comprehensive insights into the Focal Segmental Glomerulosclerosis market size, share, Focal Segmental Glomerulosclerosis epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market…
Beta-thalassemia Market is Predicted to Exhibit Remarkable Growth During the For …
To counter unmet market needs and provide better treatment choices for beta-thalassemia, several market players are working robustly either on single-agent novel molecules or on combination and dose modification of standard therapies. Several therapies are expected to be launched in the near future, likely to drive market growth during the study period. Bluebird Bio, Agios Pharmaceutical, Ionis Pharmaceutical, and others are the leading pharma and biotech players in the beta…
Sickle Cell Anemia Therapeutics Market to Witness Huge Growth by Key Players: Ir …
The Sickle Cell Anemia Therapeutics market research report delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. The Sickle Cell Anemia Therapeutics report also incorporates the current and future global market outlook in the emerging and developed markets. Moreover, the report also investigates regions/countries expected to witness the fastest growth rates during the forecast period.
The Sickle Cell Anemia Therapeutics research report also provides…
